HONG KONG – China and U.S.-based Zai Lab Ltd. has inked a deal to develop and commercialize Turning Point Therapeutics Inc.’s lead drug candidate, repotrectinib, in the greater China markets.
BEIJING – China this week approved both the country’s first mRNA vaccine candidate and its first recombinant protein subunit vaccine to begin clinical trials to fight COVID-19. China National Biotec Group (CNBG)’s vaccine is also entering phase III trials in Beijing, Wuhan and Abu Dhabi, the United Arab Emirates (UAE).
BEIJING – Beijing-based cellular immunotherapy firm Immunotech Biopharm Ltd. said June 28 that it intends to raise up to HK$1.1 billion (US$141.9 million) on the Hong Kong Stock Exchange (HKEX) on July 10, with shares priced between HK$10.5 and HK$11 apiece.
Hong Kong – China’s Kangji Medical Holdings Ltd. has made a memorable debut on the Hong Kong Stock Exchange (HKEX), with shares jumping 98.84% from their opening price of HK$13.88 (US$1.79) to close at HK$27.60 (US$3.56) on the first day of trading on June 29.
Chinese scientists at Peking University (PKU) in Beijing have developed a new in vitro patient-derived tumor-like cluster (PTC) model, which predicted the outcomes of neoadjuvant and conventional chemotherapies in colon, gastric and breast cancer patients, with a clinical consistency of >93%.
BEIJING – Beijing-based cellular immunotherapy firm Immunotech Biopharm Ltd. said June 28 that it intends to raise up to HK$1.1 billion (US$141.9 million) on the Hong Kong Stock Exchange (HKEX) on July 10, with shares priced between HK$10.5 and HK$11 apiece.
BEIJING – China this week approved both the country’s first mRNA vaccine candidate and its first recombinant protein subunit vaccine to begin clinical trials to fight COVID-19.
BEIJING – Chinese state-backed vaccine developer China National Biotec Group (CNBG), of Beijing, said on June 16 that its inactivated COVID-19 vaccine candidate produced a seroconversion rate of up to 100% in a phase I/II trial that enrolled 1,120 healthy subjects.
Makers of devices for ablation for atrial fibrillation (AF) have struggled at times to overcome clinician skepticism, but a new report in a respected medical journal might persuade some of those cardiologists. A study of nearly 28,000 AF patients in South Korea demonstrated that device therapy yielded lower rates of death and admission for heart failure compared to medical therapy, suggesting that ablation is a valid alternative to medical therapy, at least for patients in Asia.
China-based precision oncology company Genetron Holdings Ltd. and prenatal molecular testing company Progenity Inc. each successfully priced an IPO. This is just the latest demonstration that molecular diagnostics is gaining real traction when it comes to investment.
RSS
